Skip to main content

Table 4 Prevalence of MetS component by gender according to the Interim consensus (IDF-C) or the modified NCEP ATP III (ATP III-M) criteria

From: Prevalence of metabolic syndrome among urban community residents in China

  

Met 0 criteria

Met 1 criteria

Met 2 criteria

Met 3 criteria

Met 4 criteria

Met 5 criteria

 

Gender

Age

[n(%)]

[n(%)]

[n(%)]

[n(%)]

[n(%)]

[n(%)]

Total

  

IDF-Ca

ATPIII-Mb

IDF-Ca

ATPIII-Mb

IDF-Ca

ATPIII-Mb

IDF-Ca

ATPIII-Mb

IDF-Ca

ATPIII-Mb

IDF-Ca

ATPIII-Mb

 
 

32-44

693(46.5)

791(53.1)

456(30.6)

467(31.4)

219(14.7)

171(11.5)

86(5.8)

49(3.3)

31(2.1)

11(0.7)

4(0.3)

0(0.0)

1489

 

45-54

1145(24.5)

1344(28.8)

1368(29.3)

1558(33.3)

1076(23.0)

1062(22.7)

667(14.2)

539(11.5)

321(6.9)

155(3.3)

98(2.1)

17(0.4)

4675

Female

55-64

555(14.2)

657(16.8)

915(23.5)

1082(27.7)

1019(26.0)

1150(29.5)

814(20.9)

722(18.5)

448(11.5)

257(6.6)

153(3.9)

36(0.9)

3904

 

65-74

109(6.0)

121(6.6)

298(16.4)

387(21.2)

507(27.8)

605(33.2)

493(27.1)

511(28.1)

300(16.5)

174(9.6)

114(6.2)

23(1.3)

1821

 

≥75

66(3.9)

87(5.2)

271(16.2)

341(20.4)

472(28.2)

594(35.4)

490(29.2)

466(27.8)

277(16.5)

166(9.9)

100(6.0)

22(1.3)

1676

 

Total

2568(18.9)

3000(22.1)

3308(24.4)

3835(28.3)

3293(24.3)

3582(26.4)

2550(18.8)

2287(16.9)

1377(10.1)

763(5.6)

469(3.5)

98(0.7)

13565

 

32-44

253(29.4)

344(40.0)

256(29.7)

226(26.2)

187(21.7)

179(20.8)

111(12.9)

87(10.1)

43(5.0)

20(2.3)

11(1.3)

5(0.6)

861

 

45-54

409(16.9)

536(22.2)

545(22.5)

709(29.3)

636(26.3)

603(24.9)

518(21.4)

394(16.3)

253(10.5)

153(6.3)

58(2.4)

24(1.0)

2419

Male

55-64

328(11.2)

475(16.2)

678(23.1)

880(30.0)

827(28.2)

794(27.1)

684(23.4)

546(18.7)

337(11.5)

204(7.0)

76(2.6)

31(1.1)

2930

 

65-74

123(8.4)

173(11.8)

304(20.6)

450(30.5)

455(30.9)

435(29.5)

378(25.6)

298(20.2)

176(11.9)

97(6.6)

38(2.6)

21(1.4)

1474

 

≥75

92(7.6)

124(10.3)

295(24.4)

402(33.3)

378(31.3)

360(29.8)

277(23.0)

212(17.5)

132(10.9)

91(7.5)

34(2.8)

19(1.6)

1208

 

Total

1205(13.6)

1652(18.6)

2078(23.3)

2667(30.0)

2483(27.9)

2371(26.7)

1968(22.1)

1537(17.3)

941(10.6)

565(6.3)

217(2.5)

100(1.1)

8892

Overall

32-44

946(40.3)

1135(48.3)

712(30.3)

693(29.5)

406(17.3)

350(14.9)

197(8.4)

136(5.8)

74(3.1)

31(1.3)

15(0.6)

5(0.2)

2350

 

45-54

1554(21.9)

1880(26.5)

1913(27.0)

2267(32.0)

1712(24.1)

1665(23.5)

1185(16.7)

933(13.2)

574(8.1)

308(4.3)

156(2.2)

41(0.5)

7094

 

55-64

883(12.9)

1132(16.6)

1593(23.3)

1962(28.7)

1846(27.0)

1944(28.4)

1498(21.9)

1268(18.6)

785(11.5)

461(6.7)

229(3.4)

67(1.0)

6834

 

65-74

232(7.0)

294(8.9)

602(18.3)

837(25.4)

962(29.2)

1040(31.6)

871(26.4)

809(24.6)

476(14.5)

271(8.2)

152(4.6)

44(1.3)

3295

 

≥75

158(5.5)

211(7.3)

566(19.6)

743(25.8)

850(29.5)

954(33.1)

767(26.6)

678(23.5)

409(14.2)

257(8.9)

134(4.6)

41(1.4)

2884

 

Total

3773(16.8)

4652(20.7)

5386(24.0)

6502(29.0)

5776(25.7)

5953(26.5)

4518(20.1)

3824(17.0)

2318(10.3)

1328(5.9)

686(3.1)

198(0.9)

22457

  1. a IDF-C (joint interim consensus criteria by IDF and other organization): Diabetes or fasting glucose ≥ 100 mg/dL; Hypertension or SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; Dyslipidemia or HDL < 40 mg/dL for men and HDL < 50 mg/dL for women; Dyslipidemia or Triglycerides ≥ 150 mg/dL; Waist circumference ≥ 85 cm for men and ≥ 80 cm for women.
  2. b ATP III-M (modified NCEP ATP III criteria): Diabetes or fasting glucose ≥ 110 mg/dL; Hypertension or SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; Dyslipidemia or HDL < 40 mg/dL for both men and women; Dyslipidemia or Triglycerides ≥ 150 mg/dL; Waist circumference ≥ 90 cm for men and ≥ 80 cm for women.